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Introduction
Both high-risk MDS and AML require new therapeutic approaches. On theoretical grounds, such approaches should target transformed cells and cause them to initiate at least one of three distinct, yet interwoven biological processes: (i) cell death by apoptosis, (ii) preferentially irreversible cell cycle blockade or (iii) terminal differentiation.
A recent overall trend in oncology is the conception of so-called targeted therapies in which oncogenic events or surface markers are taken advantage of to disrupt the essential transforming event and to selectively destroy tumor cells with a maximum of specificity and a minimum of side effect on non-transformed cells 1 . Examples of such targeted therapies applied to hematological malignancies include selective tyrosine kinase inhibitors (with imatinib as a ground-breaking paradigm for the treatment of chronic myeloid leukemia). For the treatment of solid tumors, quintessential examples are the small inhibitory compounds targeting the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) 2 . Such small molecules directed against the EGFR include gefitinib and erlotinib [3] [4] [5] .
Surprisingly, a recent study revealed the capacity of gefitinib to induce differentiation in three AML cell lines (U937, HL60, and Kasumi-1) which all lack expression of the EGFR 6 , thus unraveling an interesting off-target effect of a compound that was believed to specifically act on EGFR-expressing cells. Based on this report, we studied the effects of the EGFR inhibitor erlotinib on EGFR-negative AML and MDS cells. Here, we report that erlotinib has an antineoplastic activity on MDS and AML cells that includes a pro-apoptotic effect. The
therapeutic efficacy of erlotinib is demonstrated in vitro, ex vivo on MDS/AML-derived
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From malignant myeloblasts, as well as in vivo. Based on these data, we propose the therapeutic offtarget use of erlotinib for the treatment of high-risk MDS and AML.
Patients, Materials and Methods

Patients
Samples from 31 patients or healthy volunteers were assessed in our study (Table 1) .
Informed consent of all patients and healthy subjects was provided according to the For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From all assays assessing the differentiation-inducing capacity of erlotinib were carried out in the presence ("DMSO") as well as in absence of DMSO ("control"). To inhibit activation of caspases cells were incubated with 100µM z-VAD-fmk. Apoptotic cells were detected by cytoflourometric analysis using a FACScan (Becton Dickinson, Mountain View, CA) as described previously 7, 8 . Cells were stained with propidium iodide (PI; 5µg/mL; Sigma, Steinheim, Germany) and concomitantly with either 40nM fluorochrome DiOC 6 (3) (3,3 dihexyloxacarbocyanine iodide; Molecular Probes, Eugene, OR, USA) for 15 minutes at 37°C, or Annexin-V-FITC (Becton Dickinson) following the manufacturer's instructions to determine the mitochondrial transmembrane potential or phosphatidyl serine exposure, respectively [9] [10] [11] .
For conventional cell cycle analysis, cells were harvested, washed in PBS and stained with propidium iodide (PI, 25 µg/ml, Sigma) followed by an incubation period of 30 min at 37°C.
Subsequently, cell cycle distribution was determined by cytofluorometric analysis using a
FACS Vantage (Becton Dickinson).
Changes in proliferation were assessed by adding a predefined amount of immunoflourescent beads (AlignFlow, Invitrogen, Karlsruhe, Germany), emitting a signal at 488nm to 300µl of the cells cultured in suspension following the manufacturer`s instructions. In the subsequent flourocytometric analysis 3000 events elicited by the beads were counted with the concomitantly acquired number of cultured cells, allowing quantification of cell numbers in relation to the number of beads.
To flourocytometrically assess differentiation, cells were harvested, washed and stained with a PE-conjugated anti-CD11b antibody (clone ICRF44, Becton Dickinson) indicating myelocytic differentiation as described previously 12 . Isotypic mouse IgG1 (Becton Dickinson) was used to set threshold parameters.
Morphological assessment of differentiation and apoptosis was carried out following WrightGiemsa staining of cytospins. To quantify differentiation and apoptosis at least 100 cells of each condition were assessed for signs of differentiation (decrease of cytoplasmic basophilia, appearance of granulation, lobulation of the nucleus) or apoptosis (chromatin condensation and nuclear fragmentation).
Analysis of the phosphoproteome
Differential expression of phosphoproteins was assessed in KG-1 cells cultured 8h in the presence of 10 µM erlotinib or 0,02% DMSO. Analysis was carried out using the Kinex 
Flourocytometric assessment of STAT-5 activation
Cells were harvested, washed and subsequently fixed and permeabilized using the BD Cytofix/Cytoperm kit (Becton Dickinson) following the manufacturer`s instructions. Cells were first stained with the primary antibody detecting activated STAT-5 (P-Tyr694, Cell Signaling), followed by staining with a secondary FITC-conjugated antibody. Isotypic controls were used to set threshold parameters.
Knock-down of proteins by small interfering RNA (siRNA)
Cells were transfected with the Nucleofactor system (Amaxa, Cologne, Germany) as described previously 12 
Immunoblot analysis
Lysates from 5x10 6 Dharmacon. Blots were stained with either goat anti-rabbit peroxidase-labeled or goat antimouse peroxidase-labeled secondary antibody (Amersham, Arlington Heights, IL, USA) and were revealed using an enhanced chemiluminescence detection system (Amersham).
Immunofluorescence
Cells of patients or cell lines were allowed to adhere on polylysine-L coverslips (Sigma) and were fixed in 4% paraformaldehyde at room temperature. Cells were then permeabilized with 
Evaluation of the therapeutic efficacy of erlotinib in a murine leukemia model
Antileukemic activity of erlotinib was evaluated in female, severe combined immunodeficient (SCID) mice (Charles River, Wilmington, MA). Animals were housed in suitable cages under specified pathogen-free conditions in rooms maintained at 23°C and 50% humidity, with a 12-hour light/12-hour dark cycle. The mice were quarantined during the acclimatization period of at least a week. Food (Standard 1320 and 1430; Altromin, Lange, Germany) and acidified water (pH 2.5-3.0) were available ad libitum. Mice (in groups of 4) were injected intraperitoneally with 1×10 6 KG-1 cells on day 0 as described previously 13 . Mice were then randomly assigned to the treatment or control group. Treatment was initiated on day 7
following intraperitoneal injection of tumor cells. The treatment group received a daily dose
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From of 100mg/kg erlotinib (diluted in sterile water and 10% DMSO) orally on five consecutive days, followed by a treatment pause of two days. Mice in the control group received water/DMSO accordingly. Mice were controlled daily for signs of toxicity and tumor/aszites development. Xenografts were measured daily in two dimensions with a caliper. At the end of the studies, all animals were euthanized by cervical dislocation under isoflurane (1-chloro-2,2,2-trifluoroethyldifluoromethylether; CuraMED Pharma, Karlsruhe, Germany) anesthesia.
Explanted tumor and specimen investigations
Explanted tumors were fixed in 3.8% buffered formaldehyde, embedded in Paraplast (Sherwood Medical, Norfolk, NE), and 5 µm sections prepared. For histopathologic examination, sections were stained with hematoxylin/eosin (HE) and examined by light microscopy at x200 magnification by a certified histopathologist. To assess the presence of malignant cells in the ascites, peritoneal exudate was collected by peritoneal lavage and cells were visualized on cytospins by Wright-Giemsa staining.
Statistics
Statistics were analyzed using Excel Software (Microsoft, Redmond, WA), SPSS software (SAS Institute, Cary, NC), and Scion Image 4.0 (Scion Corporation, Frederick, MD). Tumorfree survival in mice was analyzed by using the Kaplan-Meier method. Statistical significance was determined employing the log-rank test. Apoptosis induced by erlotinib in ex vivo cells of the MDS and AML subgroups is depicted using a boxplot graph, statistical significance was assessed using the Student's t-test.
Results
Off-target effects of erlotinib on MDS/AML cell lines
In contrast to the non-small cell lung cancer cell line A549, the AML cell lines KG-1 and HL60 as well as the MDS-derived cell line P39 lack EGFR expression ( Figure 1A ), meaning that any effect of the bona fide EGFR antagonist erlotinib on these cells must be considered as "off-target". Erlotinib efficiently induced the apoptosis-associated phosphatidylserine exposure (detected with Annexin V-FITC conjugates) followed by the loss of viability (detected with the vital dye propidium iodide, PI) in KG-1 cells ( Figure 1 , B and C), yet failed For personal use only. on October 28, 2017. by guest www.bloodjournal.org From to do so in P39 ( Figure 1D ) and HL60 cells ( Figure 1E ). Erlotinib also reduced the absolute number of viable KG-1 (and to a lesser extent the viability of P39 or HL60 cells) cells ( Figure   1F and G). Phosphoproteome analysis of KG-1 cells revealed that erlotinib influenced the phophorylation status of numerous proteins (data not shown), including the retinoblastoma (Rb) protein, which is critical for G 1 /S transition of the cell cycle 14 , as well as the plateletderived growth factor receptors PDGFRα and PDGFRβ, which are involved in hematopoietic differentiation 15, 16 . We therefore assessed the effect of erlotinib on cell cycle progression and differentiation of malignant myeloblasts.
Erlotinib had no effect on the total levels or Rb protein, yet reduced the phosphorylation of For personal use only. on October 28, 2017. by guest www.bloodjournal.org From patients with MDS and AML confirmed that an increasing fraction of patients -but not the healthy volunteers -manifested a strong (>20%) apoptosis induction upon erlotinib administration ( Figure 7I ). We could not correlate the therapeutic response with the mutational status of NPM-1 (because only one AML patient in our cohort carried a NPM-1 mutation).
In vivo and ex vivo effects of erlotinib on malignant cells of MDS and AML
During the course of our study, we had the opportunity to evaluate the in vivo effects of erlotinib in a patient diagnosed with two malignancies: a metastatic EGFR-positive non-small cell lung cancer (NSCLC) and a high-risk MDS (RAEB-2) with a normal karyotype. 
, who initially received a monotherapy with erlotinib, achieved a complete remission of his AML that was maintained for several months 29 .
From a more general point of view, the results presented here confirm an emerging concept in the field of targeted anti-cancer therapy: targeted therapies do not only work through an action on the molecular target that they were originally designed for. As an example, imatinib was rationally designed to antagonize the deregulated tyrosine kinase activity of Bcr-Abl (and hence to treat leukemias bearing the Philadelphia chromosome creating the Bcr-Abl fusion oncogene) 30 . However, later imatinib turned out to be useful for the treatment of malignancies relying on the activating mutation of c-kit (in gastrointestinal stroma cell tumors) or the PDGFR (in hypereosinophilic syndrome) 31, 32 . In experimental models, imatinib can even cause the regression of tumors in vivo that do not respond to the drug in vitro, presumably though the inhibition of non-mutated tyrosine kinases expressed by the host immune system 33, 34 . From this viewpoint, the present report adds another example of a therapeutically warranted off-target effect of tyrosine kinase inhibitors. Through a hitherto unexplained molecular pathway, the EGFR antagonist erlotinib kills MDS and AML cells that lack the EGFR. Needless to say, that this discovery may constitute a first step towards a novel therapeutic application of this tyrosine kinase inhibitor.
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